Commonwealth Fund July 30, 2021
President Biden signed an executive order to promote competition in prescription drug markets — a move aimed at lowering drug costs
The order lays out actions for federal agencies to address anticompetitive behaviors of drug manufacturers and explore tactics to increase the use of generic drugs and biosimilars
Earlier this month, President Biden signed an executive order, Promoting Competition in the American Economy. The order lays out actions to address consolidation in health care markets and price competition in the prescription drug markets. The administration has indicated that lowering drug prices is a priority and instructed agencies to act. In addition, Congress is working to move drug pricing reform this year. A comprehensive approach is needed that focuses on...